GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kilitch Drugs (India) Ltd (BOM:524500) » Definitions » Asset Turnover

Kilitch Drugs (India) (BOM:524500) Asset Turnover : 0.22 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kilitch Drugs (India) Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Kilitch Drugs (India)'s Revenue for the three months ended in Dec. 2024 was ₹562 Mil. Kilitch Drugs (India)'s Total Assets for the quarter that ended in Dec. 2024 was ₹2,594 Mil. Therefore, Kilitch Drugs (India)'s Asset Turnover for the quarter that ended in Dec. 2024 was 0.22.

Asset Turnover is linked to ROE % through Du Pont Formula. Kilitch Drugs (India)'s annualized ROE % for the quarter that ended in Dec. 2024 was 12.59%. It is also linked to ROA % through Du Pont Formula. Kilitch Drugs (India)'s annualized ROA % for the quarter that ended in Dec. 2024 was 9.19%.


Kilitch Drugs (India) Asset Turnover Historical Data

The historical data trend for Kilitch Drugs (India)'s Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kilitch Drugs (India) Asset Turnover Chart

Kilitch Drugs (India) Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.39 0.55 0.65 0.67

Kilitch Drugs (India) Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.18 0.14 0.18 0.22

Competitive Comparison of Kilitch Drugs (India)'s Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kilitch Drugs (India)'s Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Asset Turnover distribution charts can be found below:

* The bar in red indicates where Kilitch Drugs (India)'s Asset Turnover falls into.


;
;

Kilitch Drugs (India) Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Kilitch Drugs (India)'s Asset Turnover for the fiscal year that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=1536.062/( (2195.213+2400.616)/ 2 )
=1536.062/2297.9145
=0.67

Kilitch Drugs (India)'s Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=561.661/( (2594.253+0)/ 1 )
=561.661/2594.253
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Kilitch Drugs (India)  (BOM:524500) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Kilitch Drugs (India)'s annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=238.436/1893.204
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(238.436 / 2246.644)*(2246.644 / 2594.253)*(2594.253/ 1893.204)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.61 %*0.866*1.3703
=ROA %*Equity Multiplier
=9.19 %*1.3703
=12.59 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Kilitch Drugs (India)'s annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=238.436/2594.253
=(Net Income / Revenue)*(Revenue / Total Assets)
=(238.436 / 2246.644)*(2246.644 / 2594.253)
=Net Margin %*Asset Turnover
=10.61 %*0.866
=9.19 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Kilitch Drugs (India) Asset Turnover Related Terms

Thank you for viewing the detailed overview of Kilitch Drugs (India)'s Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Kilitch Drugs (India) Business Description

Traded in Other Exchanges
Address
Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in the manufacture and sales of pharmaceutical products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, HPURE, and others. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.

Kilitch Drugs (India) Headlines

No Headlines